Investor Relations

NYSE: NVRO

Price

73.74 -0.10 ( -0.14% ) 4:02 6/26/17 Pricing delayed 20 minutes

Volume 323,756

Recent News

See All
June 15, 2017 Neurosurgery Selects the SENZA-RCT 24-Month Outcomes Publication as the Top Pain Paper of the Year
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that Neurosurgery , the official journal of the Congress of Neurological Surgeons (CNS), selected the SENZA-RCT 24-month outcomes publication as the journal's Top Pain Paper of the Year.  The SENZA-RCT is a groundbreaking pivotal study that was both the largest prospective randomized clinical trial ever conducted to assess the treatment of chronic back and leg pain, and the first to evaluate comparative effectiveness of spinal cord stimulation (SCS) therapies. Each paper was subject to a rigorous review process with the journal's editorial board, beginning with initial selection from the entire pool of papers published between June 2016 and June 2017.  "The CNS is committed to providing relevant and informative science to our members. This paper delivers on that commitment, and improves our field through innovation. This...
May 30, 2017 Nevro to Present at the William Blair Growth Stock Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that its management will be presenting at the William Blair Growth Stock Conference on Tuesday, June 13, 2017 in Chicago.  Nevro management is scheduled to present at 10:10 a.m. CT.  The presentation will be accessible via a live audio webcast, accessible in the "Investors" section of the company's website at: http://www.nevro.com/investors.  Following the presentation, an archived copy will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California , Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza System is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.